Phase 3 study to investigate the efficacy and safety of the oral FXIa inhibitor Asundexian (BAY 2433334) compared with placebo in participants after an acute non cardioembolic ischemic stroke or high-risk TIA

  • Singhal, Shaloo (Primary Chief Investigator (PCI))

Project: Research

Project Details

Project Description

OCEANIC-STROKE (Phase 3 program of the Oral faCtor Eleven A iNhibitor AsundexIan as novel anti-thrombotiC –STROKE study
HREC Reference Number: HREC 232/22
SSA Reference: SSA/91230/MonH-2023-373553(v2)
Monash Health Local Reference: RES-23-0000-276X
Protocol Number: 20604
AcronymOCEANIC-STROKE
StatusActive
Effective start/end date9/06/23 → 8/06/28

Clinical Trial Phase

  • Phase III (a & b)